Results 171 to 180 of about 71,002 (280)

Recurrent patterns and prognostic factors based on CA-125 and RECIST progression in ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors. [PDF]

J Ovarian Res
Zhang B, Lv W, Fu Z, Zhou Y, Du J, Yao Q, Qian Q, Bu H.   +7 more
europepmc   +1 more source

Clinical implications and practical considerations for poly-ADP-ribose polymerase inhibitors as a new horizon for the management of urothelial carcinoma of the bladder. [PDF]

Investig Clin Urol, 2022
Lee HW, Seo HK.
europepmc   +1 more source

Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death [PDF]

, 2019
al., et, Ellenberger, Tom, Houl, Jerry H., Kim, In-Kwon, Stegeman, Roderick A.   +4 more
core   +1 more source

Socioeconomic and Demographic Factors in Genetic Testing Utilization Among Advanced Prostate Cancer Patients

The Prostate, Volume 86, Issue 8, Page 941-948, June 2026.
ABSTRACT Purpose Germline genetic testing in patients with advanced prostate cancer (PCa) is underutilized and hypothesized to be impacted by socioeconomic and demographic factors. This single institution, retrospective study assessed the association of income and social vulnerability with genetic referrals and testing.
Alexandra T. Skowron, Karen Childers, Courtney M. Rose, Kyle C. McElyea, Avery K. Supernois, Yousuf Hussain, Mohammed Baseer, Sunita Ghosh, Clara Hwang   +8 more
wiley   +1 more source

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations. [PDF]

Front Pharmacol, 2021
Xu Q, Li Z.
europepmc   +1 more source

Metformin as a Multifaceted Therapeutic Agent for Gastrointestinal Diseases: Mechanisms, Clinical Efficacy, and Future Directions

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT The high prevalence of gastrointestinal (GI) diseases and their significant impact on the quality of life require new therapeutic strategies. The development of novel therapeutic strategies should prioritize targeting the fundamental pathophysiological mechanisms underlying these diseases, including inflammation, cellular proliferation, and ...
Sayedeh Azimeh Hosseini, Hassan Valadbeigi, Seyedeh Mahdieh Khoshnazar, Saeed Khoshnood, Shahab Falahi, Delsuz Rezaee, Ali Hematian, Mohammad Hossein Haddadi   +7 more
wiley   +1 more source

Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. [PDF]

Oncotarget, 2022
Ueno D, Vasquez JC, Sule A, Liang J, van Doorn J, Sundaram R, Friedman S, Caliliw R, Ohtake S, Bao X, Li J, Ye H, Boyd K, Huang RR, Dodson J, Boutros P, Bindra RS, Shuch B.   +17 more
europepmc   +1 more source

Protein design and RNA design: Perspectives

Quantitative Biology, Volume 14, Issue 2, June 2026.
Abstract Advances in deep learning and generative modeling have transformed the landscape of protein and RNA design, enabling rapid and precise creation of novel biomolecules with tailored structures and functions. In protein design, generative deep learning frameworks now support backbone generation, sequence optimization, and joint sequence–structure
Xi Chen, Xu Dai, Peilong Lu
wiley   +1 more source

Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors. [PDF]

Curr Breast Cancer Rep
Ray A, Opyrchal M.
europepmc   +1 more source

Pharmacological Poly (ADP-Ribose) Polymerase Inhibitors Decrease Mycobacterium tuberculosis Survival in Human Macrophages. [PDF]

Front Immunol, 2021
van Doorn CLR, Steenbergen SAM, Walburg KV, Ottenhoff THM.   +3 more
europepmc   +1 more source